home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 10/08/19

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - Axsome Therapeutics: Sizable Sales Upside From A Promising Trial Demands A Premium

Investment Thesis Backed by positive results from a phase 02 trial for Major Depressive Disorder ((MDD)), the shares of Axsome Therapeutics, Inc. ( AXSM ) have jumped nearly seven times in 2019 so far. Out of the six clinical trials currently in progress, four data readouts will be availab...
VTGN - VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif. , Oct. 8, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, announced today that th...

VTGN - AU, HMY among premarket gainers

Sintx Technologies (NASDAQ: SINT ) +53% . More news on: Sintx Technologies, Inc., Valeritas Holdings, Inc., MDJM Ltd., Stocks on the move, Read more ...

VTGN - Blair likes VistaGen in premarket analyst action

VistaGen Therapeutics ( OTC:VTGN ) initiated with Outperform rating and $7 (+999% upside) price target at William Blair. Shares up  8%  premarket. More news on: VistaGen Therapeutics, Inc., Catalent, Inc., Cerus Corporation, Healthcare stocks news, Stocks on the move, , Read ...
VTGN - VistaGen Therapeutics EPS misses by $0.04

VistaGen Therapeutics ( OTC:VTGN ): Q1 GAAP EPS of -$0.15 misses by $0.04 . More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

VTGN - VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial resu...

VTGN - VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray

Previously completed Phase 2a clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only one week of administration Phase 2b clinical trial for treatment of Major Depressive Disorder (MDD) planned f...
VTGN - VistaGen Therapeutics EPS beats by $0.01

VistaGen Therapeutics ( OTC:VTGN ): FY GAAP EPS of -$0.90 beats by $0.01 . More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

VTGN - VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / June 25, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today reported financial results for its...

VTGN - VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine

Significant reduction of levodopa-induced dyskinesia by AV-101 observed in "gold standard" MPTP non-human primate model of Parkinson's disease, while maintaining antiparkinsonian activity of levodopa and without causing amantadine-like adverse effects SOUTH SAN FRANCISCO, CA / ACCESSWIRE...
Previous 10 Next 10